**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 4185**

**Columns: TOPIC HIGHLIGHT**

**Asbjørn Mohr Drewes, Professor, MD, PhD, DMSc, *Series Editor***

**Ultrasonography in diagnosing chronic pancreatitis: New aspects**

Dimcevski G *et al*. Modern ultrasonography in chronic pancreatitis

Georg Dimcevski, Friedemann G Erchinger, Roald Havre, Odd Helge Gilja

**Georg Dimcevski, Roald Havre, Odd Helge Gilja,** Section of Gastroenterology, Department of Medical Gastroenterology, Haukeland University Hospital, 5021 Bergen, Norway

**Georg Dimcevski, Friedemann G Erchinger, Odd Helge Gilja,** Department of Clinical Medicine, University of Bergen, 5006 Bergen, Norway

**Friedemann G Erchinger,** Department of Medicine, Voss Hospital, 5700 Voss, Norway

**Roald Havre, Odd Helge Gilja,**National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, 5021 Bergen, Norway

**Author contributions:** All authors contributed to this work.

**Correspondence to: Georg Dimcevski*,* MD, PhD, Associate Professor, Section Head** of Gastroenterology, Department of Medical Gastroenterology, Haukeland University Hospital, Jonas Liesvei 65, 5021 Bergen, Norway.georg.dimcevski@helse-bergen.no

**Telephone:** *+*47-41-523556 **Fax:** +47-55-972950

**Received:** June 19, 2013 **Revised:** September 6, 2013

**Accepted:** September 16, 2013

**Published online:**

**Abstract**

The course and outcome is poor for most patients with pancreatic diseases. Advances in pancreatic imaging are important in the detection of pancreatic diseases at early stages. Ultrasonography as a diagnostic tool has made, virtually speaking a technical revolution in medical imaging in the new millennium. It has not only become the preferred method for first line imaging, but also, increasingly to clarify the interpretation of other imaging modalities to obtain efficient clinical decision. We review ultrasonography modalities, focusing on advanced pancreatic imaging and its potential to substantially improve diagnosis of pancreatic diseases at earlier stages. In the first section, we describe scanning techniques and examination protocols. Their consequences for image quality and the ability to obtain complete and detailed visualization of the pancreas are discussed. In the second sectionwe outline ultrasonographic characteristics of pancreatic diseases with emphasis on chronic pancreatitis. Finally, new developments in ultrasonography of the pancreas such as contrast enhanced ultrasound and elastography are enlightened.

© 2013 Baishideng. All rights reserved.

**Key words:** Ultrasonography; Pancreas; Chronic pancreatitis; Transabdominal ultrasound; Medical imaging technique; Contrast enhanced ultrasonography; Elastography; Strain imaging

**Core tip:** Pancreatic diseases include acute and chronic inflammatory diseases and neoplastic tumors. It is a clinical challenge to diagnose these patients at an early stage because biochemical and imaging signs may be unspecific and are only evident at an advanced stage of the disease. Advances in pancreatic imaging are important for early detection of pancreatic diseases. Ultrasonography, as a diagnostic tool, has undergone major technical improvements over the last decade. It still is the preferred method for first line imaging, as well as it is increasingly used to clarify findings by others imaging modalities to support decision making.

Dimcevski G, Erchinger FG, Havre R, GiljaOH. Ultrasonography in diagnosing chronic pancreatitis: New aspects.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Transabdominal ultrasonography still is the most used first line imaging modality in the diagnostic workup of abdominal diseases. Ultrasonography is, noninvasive, widely available, inexpensive, without side effects and easy to perform on a daily basis, if needed. As a “real- time” imaging modality, transabdominal ultrasonography gives first a broad overview and then can localize the “region of interest” to perform detailed evaluation and eventually determine the cause of the disease. It can also reduce the use of computed tomography, magnetic resonance pancreatography, endoscopic ultrasonography or other diagnostic methods, which are personnel-intensive and thereby costly[1,2].

Ultrasonography (US) of the pancreas is challenging, given its retroperitoneal location with overlying structures and relatively small size. The quality and thereby the clinical usefulness of the pancreatic ultrasound imaging has rapidly advanced along with the technological progress. Early works in the seventies and eighteens describe evidence of pancreatic structural changes seen by transabdominal ultrasonography of approximately two-thirds in the diagnosed chronic pancreatitis (CP) cases[3-7]. Concerning pancreatic malignancy, most early works describe, somewhat surprisingly, pathological findings in the majority of the cases, but the distinction between malignancy and chronic pancreatitis could not be achieved[3-7]. With modern, high-end scanners, experienced physicians could achieve complete imaging of the pancreas in 90% in the nineties[6]. The current sensitivity and specificity of transabdominal ultrasonography in the diagnosis of pancreatic diseases, the ability to differentiate between acute and chronic inflammation and premalignant or malignant lesions is not yet determined. Today we have real-time, high-resolution imaging, where the spatial resolution is in line with the best image quality computed tomography (CT) or magnet resonance imaging (MRI) can offer. Furthermore, the temporal resolution far exceeds that of CT, PET and MRI, which is particularly relevant for contrast-enhanced ultrasonography (CEUS). Moreover, the image quality and especially the amount of information are evolving along with the technological progression and introduction of new modalities such as of CEUS and elastography[8,9].

Figure 1 shows a standard B-mode image of the pancreas, liver and surrounding vessels with a 1-5 and 12-15 MHz transducer. A clear overview of the gland and surrounding structures can be obtained and by changing the frequencies for any depth, focus on a smaller area of interest can be achieved.

We shortly review the current and forthcoming technical modalities and methods in transabdominal ultrasonography and EUS of the pancreas with emphasis on CP. In our opinion, transabdominal ultrasonography has an important place in imaging of the pancreas, alongside CT, MRI and EUS.

**ULTRASOUND EXAMINATION**

Ultrasonographic imaging of the pancreas can be difficult given its retroperitoneal location, variety in appearance among individuals and body habitus. Overlying bowel gas and obesity are the most frequent limitations in trans-cutaneous scanning of the pancreas[10-12].

Due to the food related production of intestinal gas reflecting the ultrasound beams, every examination should be performed fasting. US examination of the pancreas includes transverse, longitudinal and angled oblique scans. Successful visualization can often be achieved by manipulations with the transducer and is directly linked to the skill and persistence of the examiner. By applying graded compression by the transducer, bowel gas can be moved away, and all the portions of the pancreatic gland; head, neck, body and tail can often be visualized. Further improvement can also be obtained by drinking two glasses of water/juice, thereby using the fluid-filled stomach as an acoustic window. Other manipulations such as; changing the patient’s position to stand or sit; let the patient turn from the supine position to oblique position or change/stop the breathing circle; let the patient “blow up the belly”, can also improve visualization of the pancreas[13].

The pancreatic tail can sometimes be difficult to access in transversal scan. Figure 2 shows trans-splenic access, where the tail of the pancreas (cauda pancreatis) is scanned from the left lateral side using the spleen as acoustic window.

In a US examination of the pancreas the echotexture, the size of the gland including the main pancreatic duct (MPD), and anatomical landmarks of the pancreas should be evaluated. The echotexture in a normal pancreas is isoechogenic or hyperechogenic compared to the healthy liver[14]. Frequently, the echogenicity of pancreas is increasing with age. Orientational antero-posterior dimensions of the pancreas are: the head (2.5 cm), body (1.5 cm), tail (3.5 cm) and the pancreatic duct (< 2.5 mm). Fatty replacement (lipomatosis) of the pancreatic gland and decrease in size is common with increasing age but can also be found in patients with cystic fibrosis, CP, some types of diabetes and other diseases[15-17].

The surrounding vascular, ductal and abdominal organ landmarks are the portal vein, splenic vein, confluens with the mesenteric vein, vena cava, aorta, superior mesenteric artery, common hepatic artery, splenic artery, common bile duct, duodenum, stomach and the liver.

**MODALITIES IN ULTRASONOGRAPHY**

***Grayscale B-mode ultrasound***

Grayscale B-mode ultrasound of the pancreas is the most used imaging modality. Complete evaluation of organ size, borders, echostructure, surrounding vessels, and pancreatic ducts can be obtained swiftly. These parameters are often sufficient to diagnose many diseases of the pancreas and patients can be managed accordingly.

***Tissue harmonic imaging***

Tissue harmonic imaging (THI) or second harmonic imaging overcomes several of the B-mode limits. By receiving harmonic overtones instead of the emitted US-frequencies, the lateral delineation is sharpened and reverberation artifacts are reduced[18]. The image quality is improved by better discrimination between liquid and solid structures increasing the spatial and contrast resolution, making millimeter sized structures detectable. Thus, ultrasonography with THI may have better resolution than CT and MRI, in the absence of extreme obesity or a large amount of intestinal gas, which may temporarily mask the pancreas[19-21]. There are only a few disadvantages of THI; reduction of frame rate, reduced penetration depth, motion artifacts and only marginal improvement of image quality in the near sound field. This modality is normally used with CEUS, which is probably the most important application of this modality[22,23].

***Doppler imaging***

The Doppler effect in ultrasound is the change in US frequency of reflected wave from an object moving relative to the ultrasound probe, adding the option to show and record blood flow direction and velocity from vessels in ultrasound imaging.

Several modalities in conventional Doppler ultrasonography exist[24]. CombiningB-mode gray scale and color-Doppler ultrasonography, overall accuracy rises substantially. By international convention, Doppler color is coded in such a way that red color expresses flow towards the ultrasound transducer, while blue color expresses flow away from the transducer. The recent technological progress, in particular increased color-Doppler sensitivity is contributing to diagnosing and staging of pancreatic diseases*.* Doppler interrogation of the gland may show the outlines of the organ more precisely, since the pancreas is surrounded by vessels. The normal intrapancreatic vessels are small and difficult to show in conventional Doppler imaging. Color-Doppler shows flows in normal surrounding vessels and abnormal vascularity, such as in tumors with high vessel infiltration or tumor infiltration in vessels[25]. This method can also discriminate between cystic avascular processes without blood flow and aneurisms. Very small pancreatic calcifications which can be hard to distinguish in the irregular parenchymal pancreatic tissue in CP can be identified by the presence of twinkling artifacts. Modern high- end scanners can distinguish between inflammation (high flow) and infarction without flow[26].

**METHODS IN ULTRASONOGRAPHY**

***Panoramic imagin*g**

In a conventional ultrasound field of view, only parts of the pancreas are visible in one image. With the panorama technique, based on real time image reconstruction the whole pancreas can be displayed in one image, allowing the creation of images similar to those in CT and MRI. However, the usefulness of these computed images regarding the evaluation of pancreatic disorders is not well documented.

***Compound imaging***

Compound imaging obtains multiple coplanar images from different angles using computed beam steering. Multiple views are integrated into a single compound image with improved tissue definition, where signals from real structures are intensified and the artifacts are suppressed[14,18,19]. Organs appear smoother with clear contours. The MPD and vessels are clearly accentuated.As these images are generated from several angles, classical signs in transabdominal ultrasonography such as cast shadows behind pancreatic calcifications or ultrasound enhancement behind pancreatic cystsare attenuated[27]*.*

***Contrast-enhanced ultrasonography***

The development of microbubble contrast agents enables the display of the vasculature, down to parenchymal microvasculature. With this technique enhancement patterns of lesions can be studied in real time in a similar way as contrast-enhanced CT or contrast-enhanced MRI, under full control of the operator[28-31]. Ultrasound contrast agents are confined to the blood pool where CT or MRI contrast agents are rapidly cleared into the extravascular space. As the contrast bubbles, approximately the size of a red blood cell, are gas-filled, they create strong acoustic reflectors within the fluid filled blood pool. An advantage of contrast-enhanced ultrasonography (CEUS) is the ability to study the dynamics of lesions in real time. The excellent tolerance and safety profiles allow repeated administrations in the same session if needed. The elimination of the contrast agent is by breathing, independent of liver and kidney function. Today, CEUS is increasingly incorporated in clinical use, alongside with traditional US, in liver lesions, which is by the far the most common use, but also in the kidneys, in vesico-ureteric reflux, in trauma and in the cerebral circulation[28].

Transabdominal ultrasonography with CEUS in the pancreas has probably near the same potential, and has in some few centers been established in diagnostic routine[14,31]. The most common application is to define pancreatic lesions, in most cases already known lesions, previously seen on CT/MRI or seen in the initial US examination. Several studies show that transabdominal CEUS can be used to differentiate malignancy and CP[32-36]. The time window in a pancreatic CEUS examination is notably shorter than in the well-known liver CEUS study. This is due to the entirely arterial blood supply of the pancreas. The enhancement of the pancreas begins almost simultaneously with the aortic enhancement and reaches its peak between 15 and 20 s after injection of the ultrasound contrast agent. After a noticeable parenchymal enhancement in the arterial early phase, there is a washout of contrast medium with gradual loss of echogenicity during the late phase for approximately 120 s[36,37].

New technologies may be able to discriminate between normal pancreatic perfusion and pathological in parenchymal pancreatic diseases or different tumor perfusion patterns that can be visualized using the small microbubbles of ultrasound contrast agents[38]. Time-intensity curves expressing arrival time of the microbubbles, time to peak or other parameters have so far not been able to show significant difference in focal masses in patients with CP and carcinomas[34]. The first generation analyzing software did not incorporate motion correction and that can be one of the reasons for the insensitivity of this method, since the pancreas moves in both planes, thereby moving the region of interest out of plane. New versions of more sophisticated analyzing software are under development. Figure 3shows an example of a CEUS examination of the pancreas with a motion tracked area of interest.

In the near future, microbubbles may be an important part of the therapeutic armaments[39]. Studies have been undertaken to investigate the ability and efficacy of sonoporation in a clinical setting to increase the overall survival in patients with pancreatic adenocarcinoma. In a pilot study, numbers of treatment cycles with gemcitabine were increased from an average of 9 to 16 cycles. In two out of five patients treated, the maximum tumor diameter was temporally decreased to 80% ± 5% and permanently to 70% ± 5% of their original size, whilst the other patients showed reduced growth. This study demonstrated that it is possible to combine ultrasound, microbubbles, and chemotherapy in a clinical setting prolonging the quality of life in patients with pancreatic adenocarcinoma when comparing to chemotherapy alone. Figure 4shows an experimental microbubble sonoporation therapy setup targeting a pancreatic adenocarcinoma, using a clinical ultrasound scanner[39].

**ENDOSCOPIC ULTRASONOGRAPHY IN THE WORKUP OF CP**

Even if transcutaneuos US may image the pancreas in many cases, the limitations of obesity, reverberations and bowel gas may not always be eliminated. Endoscopic ultrasonography (EUS) has the advantage over trans-cutaneous US examinations that the US probe can be placed close to the organ of interest allowing the use of high frequency ultrasound (5-12.5 Mhz). This may allow the imaging of small alterations in the pancreatic duct and parenchyma. The findings are usually grouped as ductal changes or parenchymal changes. The classic features include: ductal calcifications, hyperechoic duct walls, duct-caliber dilatation, visible side ducts. Parenchymal changes include: lobulation with or without honeycombing, parenchymal hyperecohic areas with or without shadowing, echogenic strands and cysts. The problem is that some of these features also are found in healthy subjects, and increasing with age. A study compared EUS and an endoscopic pancreatic function test (ePFT) sampling the peak bicarbonate concentration after secretin stimulation. EUS showed a good correlation with fibrosis. The sensitivity of EUS and ePFT had similar sensitivity for diagnosing CP (0.84%-0.86%), but EUS was more specific (100% *vs* 67%). By combining the two methods, however, the sensitivity reached 100%[40]. The Rosemont classiﬁcation is a set of EUS-based criteria for the diagnosis of CP. These criteria are based on detailed evaluation on pancreatic parenchymal and ducts. Both parenchymal and ductal features are divided in major and minor criteria[41]. Major criteria for CP are; hyperechoic foci with shadowing, lobularity with honeycombing and MPD calculi. Minor criteria for CP; cysts, dilated ducts ≥ 3.5 mm, irregular pancreatic duct contour, dilated side branches ≥ 1 mm, hyperechoic duct wall, strands, nonshadowing hyperechoic foci, and lobularity with noncontiguous lobules. The Rosemont criteria, using a combination of major and/or minor criteria, categorize the patient into four groups: consistent, suggestive, indeterminate of CP or normal.

**NEW IMAGING METHODS FOR EUS IN CP- EUS ELASTOGRAPHY**

Elasticity imaging of pancreatic tissue may help the examiner distinguish between harder and softer tissue. Elasticity imaging is currently an option in ultrasonography. Two main methodologies are commercially available. Strain imaging provides a qualitative strain map, frequently in a colored pattern superimposed on a B-mode echogram, visualizing the local strain as a result of endogeneous movements or by an acoustic pulse. Alternatively, a shear wave method is used, providing quantitative elasticity information based on the travelling speed of shear waves. The energy for these shear waves is deposited in the tissue by an acoustic pulse. In some systems both deformation based images and local shear-wave quantification are combined.

Up to now, only strain based imaging systems have been available in combination with flexible echo-endoscopes. In Figure 5 an EUS image of a pancreas with CP is imaged with Real-Time Elastography. In Figure 6 a reactive hilar lymph node in a patient with CP is imaged as green in the strain map indicating intermediate hardness.

Several studies including two meta-analyses conclude that EUS elastography may help characterize focal pancreatic lesions as benign or malignant based on their imaged strain with an high accuracy[42-44]. In CP, the pathology is sometimes more diffusely distributed, and tissue hardness may not be limited to hypoechoic areas. Fibrosis and calcifications, if present, also increase tissue hardness in addition to local edema. In a transcutaneous shear wave study of acute pancreatitis Mateen et al[42] found that pancreatic tissue undergoes a cycle of increasing tissue hardness, resulting in low strain, in the acute phase of inflammation which subsequently turned softer as the inflammatory reaction resolved. In a study on focal pancreatic lesions we found that hypoechoic lesions that turned out to be inflammatory in origin were significantly softer than the malignant lesions. However, these lesions were imaged at a median of 8 months after the last inflammatory attack (range: 1.2-12 months). It is our experience that inflammatory lesions in the pancreas may present with a wide range of tissue strain. If a high-strain area (indicating soft tissue) is found, corresponding to a hypoechoic area in a sonogram, the chance of finding malignancy is however low (abstract Havre, UEGW 2011).

**INFLAMMATORY DISEASES OF THE PANCREAS**

In the following morphological and sonographic characteristics of pancreatic diseases with emphasis on CP will be outlined. Pancreatic neoplasms are also shortly described as an important differential diagnosis.

***Acute pancreatitis***

Acute pancreatitis is an acute inflammatory process that may include interstitial edema, necrosis, hemorrhage of pancreatic tissue and fluid collections, depending on the severity of the inflammation. The changes can be focal enlargement or diffuse, depending on its distribution and sometimes difficult to differentiate, especially when acute pancreatitis occurs in a patient with CP. Furthermore, focal pancreatitis often occurs in the pancreatic head, as a hypoechoic mass and not easily distinguishable from a tumor or changes seen in CP. The introduction of CEUS and its ability to differentiate between avascular necrotic tissue, cysts, abscesses and normal or hypervascular inflamed tissue equates US with CT[45]. CEUS has bedside availability, better cost effectiveness and can also be used in those patients where CT contrast agents are contraindicated. However, visualization of the whole gland can be a problem in very obese patients.

***Chronic pancreatitis***

Classical diagnostic findings of CP in transabdominal ultrasonography reflects the spectrum of pancreatic disorders in CP. Ranging from progressive and irreversible morphological and functional derangement, inflammatory episodes and obstruction of structures adjacent to the pancreas[46].

Late stage, severe CP is normally easily recognizable due to characteristic morphological changes. The presences of pancreatic or intraductal calcifications presented as hyperechoic foci are pathognomonic[47]. Caliber abnormalities such as a dilated and irregular pancreatic duct is seen with a sensitivity of approximately 70%[48]. The reported sensitivity is probably due to limited duct changes in early/mild and moderate CP, where the pancreatic duct is less than 3 mm in diameter[49]. Pseudocysts may cause benign duct obstruction (stricture) and dilatation upstream[50]. Solid or cystic lesions and malignant infiltration, especially if contiguous to the main duct, may also cause duct compression, with progressive development of obstructive CP upstream. A small atrophic gland with focal alterations and parenchymal heterogeneity is easily identified in advanced stages. Figure 7(B-mode US***)*** and8(CEUS image of the pancreas in the early arterial phase)shows typical morphological changes in advanced CP.

In moderate to severe CP, the pancreatic gland echo texture is inhomogeneous and rough due to coexistence of fibrotic hyperechoic and hypoechoic focal inflammation signs[49,51,52]. These findings are reported to be observed in approximately 70% of the cases, already in the late eighties[48,53,54]. Echogenicity of the pancreas is usually increased in CP due to fibrosis and fatty infiltration. This is not a specific parameter due to presence of adipose tissue in elderly and obese patients[10,53]. Increased echogenicity of duct wall can also be detected[50].Figure 9 showan example of elastography in moderate CP.

Early stage CP is normally without or with minimal morphological changes, where imaging modality falls short in diagnosing CP. Late stages signs like calcifications or dilated and irregular main pancreatic duct are diagnostic for CP, but can also be absent in severe exocrine insufficiency, depending on the type of CP[55,56].

Cambridge classification of endoscopic retrograde pancreaticography (ERP), US and CT imaging, grades the severity of CP, based on pancreatic structural changes and abnormalities of the main duct and side branches[52]. The sensitivity in diagnosing and grading the severity of CP with ultrasound alone, compared to the morphological gold standard ERP, rose to over 80% in the late eighties[53]. With the development of endosonographic ultrasound, subtle early changes in the pancreatic echo-structure could be visualized, and a new gold standard, based on morphological criteria correlating with pathologic features emerged[57,58]. Currenttransabdominal high-end ultrasound scanners can visualize some of these criteria, although the Rosemont classification is only for EUS images. Figure 10shows minimal morphological changes in a patient with early CP, obtained by transabdominal US. Forthcoming studies comparing transabdominal ultrasonography findings with EUS criteria seem to be a logical step forward.

Pancreatic functional tests are still the only option to diagnose an early pancreatitis without morphological changes but with physiological insufficiency. Today, the short endoscopic secretin-based, pancreas function test is reasonably validated and the best available test[59,60]. This test can be combined with bedside US, to detect any morphological changes of the pancreas. Using this combined method we observed that the MPD wall had an increased echogenicity, *i.e*., hyperechoic duct wall and changes in the diameter, short after secretin was given. Data not yet published.

***Autoimmune pancreatitis***

Autoimmune pancreatitis is a benign form with autoimmune pathogenesis and a remarkable response to steroid therapy. From an imaging point of view, there are three (focal, diffuse, and combined) types of autoimmune pancreatitis where, especially the focal type can be misinterpreted as cancer[61,62]. Figure 11 shows an enlarged pancreas with a round tumorous formation, without cysts and calcification. On CEUS the affected tissue is hyperemic and shows an increased contrast-enhancement, whereas pancreatic cancer lesions are typically hypovascularized[63]. The patient avoided excessive abdominal surgery and was successfully treated with corticosteroids.

***Pseudocyst***

Pseudocysts can arise as a complication of acute pancreatitis and also often occur in CP. These cysts are well-defined, fibrous-walled anechoic structures without an epithelial lining. Pseudocysts are normally easily differentiated from pancreatic cystic tumors, where especially the premalignant and malignant forms should be identified. CEUS can classify cystic tumor’s or solid nodules through evaluation of the vascularization pattern or absence of vessels in pseudocysts[36].

***Pancreatic solid neoplasm***

Differentiation between mass-forming lesions in CP and adenocarcinomas of the pancreas are a daily challenge. The ultrasonographic findings are similar with homogeneous or inhomogeneous poorly defined hypoechoic mass in both cases[64]. After the initial detection by ultrasound, the subsequent use of CEUS, with its possibility to visualize the vascular pattern will improve the diagnostic accuracy of the lesion type. A ductal adenocarcinoma is typically hypoechoic in arterial phase without clear-cut margins, with optional central necrotic parts. On the contrary, CP has usually more vascularity, with the same enhancement patter as the surrounding pancreatic parenchyma[31,65,66]. Figure 12 shows a large hypovascularized mass with marked dilatation of the main bile duct. However, in advanced CP, due to fibrosis, inhomogenous hypovascularization can be present, making the differential diagnosis very difficult[35,67]. Differences in vascularity seen on CEUS, often correlate well with histology. Taking in account the higher temporal and spatial resolution of ultrasound into account makes CEUS equal or even superior to CT[32,34,38]. The relationship with the surrounding arterial and venous vessels, the presence of thrombosis of the portal or splenic vein are used for local staging and assessment of tumor resectability. The presence of liver metastases can also be evaluated during the late phase of the CEUS scanning procedure.

**CONCLUSION AND FUTURE PERSPECTIVES**

Today’s modern high end ultrasound scanners are still the first line modality in abdominal and pancreatic imaging. Ultrasonography is highly available, relative cheap and can be repeated on a daily basis, if needed. Ultrasound technology is developing towards smaller and really mobile scanners, implying that ultrasonography can be present in the pockets of the doctors supporting the clinical examination. With the rapid technical development, different modalities and methods, which demands computer processed images can be combined. This means highly improved image quality and diagnostic accuracy. Under good scanning conditions, ultrasonography has higher spatial resolution than CT or MRI. Furthermore, CEUS with its ability to show makro- and microvascularity is also used as a second line modality to clarify small lesions, previously detected on CT or MRI.

Regarding transabdominal ultrasound of the pancreas, we predict that the resolution and thereby the ability to detect small morphological changes will be approaching the performance of EUS. Elastography in pancreatic imaging is now well known in EUS and studies’ regarding the usefulness of this method in transabdominal ultrasonography is warranted. The ability of CEUS to visualize and quantify perfusion and thereby to characterize a given lesion or to differentiate between vascular (solid) and avascular (liquid/necrotic) components of the lesion is one of the most important progresses in pancreatic imaging today. Furthermore, the development of three-dimensional technology offers new clinical possibilities for real-time 3D volume images of the pancreas in the future.

**REFERENCES**

1 **Gilja OH**, Hatlebakk JG, Odegaard S, Berstad A, Viola I, Giertsen C, Hausken T, Gregersen H. Advanced imaging and visualization in gastrointestinal disorders. *World J Gastroenterol* 2007; **13**: 1408-1421 [PMID: 17457973]

2 **Rösch T**, Schusdziarra V, Born P, Bautz W, Baumgartner M, Ulm K, Lorenz R, Allescher HD, Gerhardt P, Siewert JR, Classen M. Modern imaging methods versus clinical assessment in the evaluation of hospital in-patients with suspected pancreatic disease. *Am J Gastroenterol* 2000; **95**: 2261-2270 [PMID: 11007227]

3 **Swobodnik W**, Meyer W, Brecht-Kraus D, Wechsler JG, Geiger S, Malfertheiner P, Junge U, Ditschuneit H. Ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the morphologic diagnosis of pancreatic disease. *Klin Wochenschr* 1983; **61**: 291-296 [PMID: 6865263 DOI: 10.1007/BF01497778]

4 **Rettenmaier G**. [Methods and results of ultrasonography in the diagnosis of pancreatic diseases]. *Leber Magen Darm* 1972; **2**: 88-90 [PMID: 5074453]

5 **Russell JG**, Vallon AG, Braganza JM, Howat HT. Ultrasonic scanning in pancreatic disease. *Gut* 1978; **19**: 1027-1033 [PMID: 730069 DOI: 10.1136/gut.19.11.1027]

6 **Reuss J**, Rettenmaier G. [Transabdominal ultrasonography in pancreatic diseases]. *Schweiz Med Wochenschr* 1993; **123**: 1049-1058 [PMID: 8511536]

7 **Fontana G**, Bolondi L, Conti M, Plicchi G, Gullo L, Caletti GC, Labo G. An evaluation of echography in the diagnosis of pancreatic disease. *Gut* 1976; **17**: 228-234 [PMID: 1269992 DOI: 10.1136/gut.17.3.228]

8 **Bamber J**, Cosgrove D, Dietrich CF, Fromageau J, Bojunga J, Calliada F, Cantisani V, Correas JM, D'Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Gilja OH, Havre RF, Jenssen C, Klauser AS, Ohlinger R, Saftoiu A, Schaefer F, Sporea I, Piscaglia F. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. *Ultraschall Med* 2013; **34**: 169-184 [PMID: 23558397 DOI: 10.1055/s-0033-1335205]

9 **Cosgrove D**, Piscaglia F, Bamber J, Bojunga J, Correas JM, Gilja OH, Klauser AS, Sporea I, Calliada F, Cantisani V, D'Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Fromageau J, Havre RF, Jenssen C, Ohlinger R, Săftoiu A, Schaefer F, Dietrich CF. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: Clinical applications. *Ultraschall Med* 2013; **34**: 238-253 [PMID: 23605169 DOI: 10.1055/s-0033-1335375]

10 **Shmulewitz A**, Teefey SA, Robinson BS. Factors affecting image quality and diagnostic efficacy in abdominal sonography: a prospective study of 140 patients. *J Clin Ultrasound* 1993; **21**: 623-630 [PMID: 8227392 DOI: 10.1002/jcu.1870210909]

11 **Fiegler W**. [Effect of various parameters on the resolution potential behind obstructing fatty tissue in sonography]. *Rofo* 1983; **139**: 85-90 [PMID: 6409738 DOI: 10.1055/s-2008-1055846]

12 **Fiegler W**, Felix R, Langer M, Schultz E. Fat as a factor affecting resolution in diagnostic ultrasound: possibilities for improving picture quality. *Eur J Radiol* 1985; **5**: 304-309 [PMID: 3910434]

13 **Dietrich CF**. Ultraschall-kurs. 5 ed. Cologne: Deutscher Ärzteverlag; 2006

14 **Erchinger F**, Dimcevski G, Engjom T, Gilja OH. Transabdominal ultrasonography of the pancreas: basic and new aspects. Imaging in Medicine. 2011; **3**: 411-22 [DOI: 10.2217/iim.11.36]

15 **Tjora E**, Wathle G, Erchinger F, Engjom T, Molven A, Aksnes L, Haldorsen IS, Dimcevski G, Raeder H, Njølstad PR. Exocrine pancreatic function in hepatocyte nuclear factor 1β-maturity-onset diabetes of the young (HNF1B-MODY) is only moderately reduced: compensatory hypersecretion from a hypoplastic pancreas. *Diabet Med* 2013; **30**: 946-955 [PMID: 23600988 DOI: 10.1111/dme.12190]

16 **Holalkere NS**, Soto J. Imaging of miscellaneous pancreatic pathology (trauma, transplant, infections, and deposition). *Radiol Clin North Am* 2012; **50**: 515-528 [PMID: 22560695 DOI: 10.1016/j.rcl.2012.03.011]

17 **Feigelson J**, Pécau Y, Poquet M, Terdjman P, Carrère J, Chazalette JP, Ferec C. Imaging changes in the pancreas in cystic fibrosis: a retrospective evaluation of 55 cases seen over a period of 9 years. *J Pediatr Gastroenterol Nutr* 2000; **30**: 145-151 [PMID: 10697132 DOI: 10.1097/00005176-200002000-00010]

18 **Hohl C**, Schmidt T, Honnef D, Günther RW, Haage P. Ultrasonography of the pancreas. 2. Harmonic imaging. *Abdom Imaging* ; **32**: 150-160 [PMID: 16850350 DOI: 10.1007/s00261-006-9017-z]

19 **Shapiro RS**, Wagreich J, Parsons RB, Stancato-Pasik A, Yeh HC, Lao R. Tissue harmonic imaging sonography: evaluation of image quality compared with conventional sonography. *AJR Am J Roentgenol* 1998; **171**: 1203-1206 [PMID: 9798848 DOI: 10.2214/ajr.171.5.9798848]

20 **Hohl C**, Schmidt T, Haage P, Honnef D, Blaum M, Staatz G, Guenther RW. Phase-inversion tissue harmonic imaging compared with conventional B-mode ultrasound in the evaluation of pancreatic lesions. *Eur Radiol* 2004; **14**: 1109-1117 [PMID: 14714139 DOI: 10.1007/s00330-003-2191-2]

21 **Spârchez Z**. Tissue harmonic imaging: is it useful in hepatobiliary and pancreatic ultrasonography? *Rom J Gastroenterol* 2003; **12**: 239-246 [PMID: 14502326]

22 **Burns PN**. Harmonic imaging with ultrasound contrast agents. *Clin Radiol* 1996; **51** Suppl 1: 50-55 [PMID: 8605774]

23 **Köster J**, Schlosser T, Pohl C, Lentz C, Lohmaier S, Veltmann C, Kuntz-Hehner S, Omran H, Lüderitz B, Becher H, Tiemann K. Blood flow assessment by ultrasound-induced destruction of echocontrast agents using harmonic power Doppler imaging: which parameters determine contrast replenishment curves? *Echocardiography* 2001; **18**: 1-8 [PMID: 11182774 DOI: 10.1046/j.1540-8175.2001.00001.x]

24 **Jerrold T**. Bushberg. Ultrasound. In: Bushberg JT, Seibert JA, Leidholdt EM, Boone JM, editors. The essential physics of medical imaging. 2 ed. Philadeplphia: Lippincott Williams & Wilkins; 2002. p. 543

25 **Gandolfi L**, Torresan F, Solmi L, Puccetti A. The role of ultrasound in biliary and pancreatic diseases. *Eur J Ultrasound* 2003; **16**: 141-159 [PMID: 12573783]

26 **Bertolotto M**, D'Onofrio M, Martone E, Malagò R, Pozzi Mucelli R. Ultrasonography of the pancreas. 3. Doppler imaging. *Abdom Imaging* ; **32**: 161-170 [PMID: 16865314]

27 **Forsberg F**. Ultrasonic biomedical technology; marketing versus clinical reality. *Ultrasonics* 2003; **42**: 17-27.

28 **Claudon M**, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, Correas JM, Darge K, Dietrich C, D'Onofrio M, Evans DH, Filice C, Greiner L, Jäger K, Jong Nd, Leen E, Lencioni R, Lindsell D, Martegani A, Meairs S, Nolsøe C, Piscaglia F, Ricci P, Seidel G, Skjoldbye B, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingham T. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. *Ultraschall Med* 2008; **29**: 28-44 [PMID: 18270887 DOI: 10.1055/s-2007-963785]

29 **Claudon M**, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. *Ultraschall Med*2013; **34**: 11-29 [PMID: 23129518 DOI: 10.1055/s-0032-1325499]

30 **Piscaglia F**, Nolsøe C, Dietrich CF, Cosgrove DO, Gilja OH, Bachmann Nielsen M, Albrecht T, Barozzi L, Bertolotto M, Catalano O, Claudon M, Clevert DA, Correas JM, D'Onofrio M, Drudi FM, Eyding J, Giovannini M, Hocke M, Ignee A, Jung EM, Klauser AS, Lassau N, Leen E, Mathis G, Saftoiu A, Seidel G, Sidhu PS, ter Haar G, Timmerman D, Weskott HP. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. *Ultraschall Med* 2012; **33**: 33-59 [PMID: 21874631 DOI: 10.1055/s-0031-1281676]

31 **Postema M**, Gilja OH. Contrast-enhanced and targeted ultrasound. *World J Gastroenterol* 2011; **17**: 28-41 [PMID: 21218081 DOI: 10.3748/wjg.v17.i1.28]

32 **D'Onofrio M**, Malagò R, Zamboni G, Vasori S, Falconi M, Capelli P, Mansueto G. Contrast-enhanced ultrasonography better identifies pancreatic tumor vascularization than helical CT. *Pancreatology* 2005; **5**: 398-402 [PMID: 15985763 DOI: 10.1159/000086540]

33 **Beyer-Enke SA**, Hocke M, Ignee A, Braden B, Dietrich CF. Contrast enhanced transabdominal ultrasound in the characterisation of pancreatic lesions with cystic appearance. *JOP* 2010; **11**: 427-433 [PMID: 20818109]

34 **Kersting S**, Konopke R, Kersting F, Volk A, Distler M, Bergert H, Saeger HD, Grützmann R, Bunk A. Quantitative perfusion analysis of transabdominal contrast-enhanced ultrasonography of pancreatic masses and carcinomas. *Gastroenterology* 2009; **137**: 1903-1911 [PMID: 19715694 DOI: 10.1053/j.gastro.2009.08.049]

35 **D'Onofrio M**, Zamboni G, Tognolini A, Malago R, Faccioli N, Frulloni L, Pozzi Mucelli R. Mass-forming pancreatitis: value of contrast-enhanced ultrasonography. *World J Gastroenterol* 2006; **12**: 4181-4184 [PMID: 16830370]

36 **D'Onofrio M**, Martone E, Malagò R, Faccioli N, Zamboni G, Comai A, Cugini C, Gubello T, Pozzi Mucelli R. Contrast-enhanced ultrasonography of the pancreas. *JOP* 2007; **8**: 71-76 [PMID: 17228138]

37 **D'Onofrio M**, Mansueto G, Falconi M, Procacci C. Neuroendocrine pancreatic tumor: value of contrast enhanced ultrasonography. *Abdom Imaging* 2004; **29**: 246-258 [PMID: 15290954 DOI: 10.1007/s00261-003-0097-8]

38 **Kersting S**, Roth J, Bunk A. Transabdominal contrast-enhanced ultrasonography of pancreatic cancer. *Pancreatology* 2011; **11** Suppl 2: 20-27 [PMID: 21464583 DOI: 10.1159/000323480]

39 **Kotopoulis S**, Dimcevski G, Gilja OH, Hoem D, Postema M. Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study. *Med Phys* 2013; **40**: 072902 [PMID: 23822453 DOI: 10.1118/1.4808149]

40 **Albashir S**, Bronner MP, Parsi MA, Walsh RM, Stevens T. Endoscopic ultrasound, secretin endoscopic pancreatic function test, and histology: correlation in chronic pancreatitis. *Am J Gastroenterol* 2010; **105**: 2498-2503 [PMID: 20606675 DOI: 10.1038/ajg.2010.274]

41 **Catalano MF**, Sahai A, Levy M, Romagnuolo J, Wiersema M, Brugge W, Freeman M, Yamao K, Canto M, Hernandez LV. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. *Gastrointest Endosc* 2009; **69**: 1251-1261 [PMID: 19243769 DOI: 10.1016/j.gie.2008.07.043]

42 **Mateen MA**, Muheet KA, Mohan RJ, Rao PN, Majaz HM, Rao GV, Reddy DN. Evaluation of ultrasound based acoustic radiation force impulse (ARFI) and eSie touch sonoelastography for diagnosis of inflammatory pancreatic diseases. *JOP* 2012; **13**: 36-44 [PMID: 22233945]

43 **Săftoiu A**, Vilmann P, Gorunescu F, Janssen J, Hocke M, Larsen M, Iglesias-Garcia J, Arcidiacono P, Will U, Giovannini M, Dietrich CF, Havre R, Gheorghe C, McKay C, Gheonea DI, Ciurea T. Efficacy of an artificial neural network-based approach to endoscopic ultrasound elastography in diagnosis of focal pancreatic masses. *Clin Gastroenterol Hepatol* 2012; **10**: 84-90.e1 [PMID: 21963957 DOI: 10.1016/j.cgh.2011.09.014]

44 **Săftoiu A**, Vilmann P, Gorunescu F, Janssen J, Hocke M, Larsen M, Iglesias-Garcia J, Arcidiacono P, Will U, Giovannini M, Dietrich C, Havre R, Gheorghe C, McKay C, Gheonea DI, Ciurea T. Accuracy of endoscopic ultrasound elastography used for differential diagnosis of focal pancreatic masses: a multicenter study. *Endoscopy* 2011; **43**: 596-603 [PMID: 21437851 DOI: 10.1055/s-0030-1256314]

45 **Rickes S**, Mönkemüller K, Malfertheiner P. Acute severe pancreatitis: contrast-enhanced sonography. *Abdom Imaging* 2007; **32**: 362-364 [PMID: 17514345 DOI: 10.1007/s00261-007-9250-0]

46 **Etemad B**, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. *Gastroenterology* 2001; **120**: 682-707 [PMID: 11179244 DOI: 10.1053/gast.2001.22586]

47 **Homma T**, Harada H, Koizumi M. Diagnostic criteria for chronic pancreatitis by the Japan Pancreas Society. *Pancreas* 1997; **15**: 14-15 [PMID: 9211487]

48 **Bolondi L**, Priori P, Gullo L, Santi V, Li Bassi S, Barbara L, Labó G. Relationship between morphological changes detected by ultrasonography and pancreatic exocrine function in chronic pancreatitis. *Pancreas* 1987; **2**: 222-229 [PMID: 3306660]

49 **Remer EM**, Baker ME. Imaging of chronic pancreatitis. *Radiol Clin North Am* 2002; **40**: 1229-142, v [PMID: 12479708 DOI: 10.1016/S0033-8389(02)00044-1]

50 **Axon AT**, Classen M, Cotton PB, Cremer M, Freeny PC, Lees WR. Pancreatography in chronic pancreatitis: international definitions. *Gut* 1984; **25**: 1107-1112 [PMID: 6479687 DOI: 10.1136/gut.25.10.1107]

51 **Siddiqi AJ**, Miller F. Chronic pancreatitis: ultrasound, computed tomography, and magnetic resonance imaging features. *Semin Ultrasound CT MR* 2007; **28**: 384-394 [PMID: 17970554 DOI: 10.1053/j.sult.2007.06.003]

52 **Sarner M**, Cotton PB. Classification of pancreatitis. *Gut* 1984; **25**: 756-759 [PMID: 6735257 DOI: 10.1136/gut.25.7.756]

53 **Jones SN**, Lees WR, Frost RA. Diagnosis and grading of chronic pancreatitis by morphological criteria derived by ultrasound and pancreatography. *Clin Radiol* 1988; **39**: 43-48 [PMID: 3276430 DOI: 10.1016/S0009-9260(88)80339-8]

54 **Alpern MB**, Sandler MA, Kellman GM, Madrazo BL. Chronic pancreatitis: ultrasonic features. *Radiology* 1985; **155**: 215-219 [PMID: 3883420]

55 **Ammann RW**, Muench R, Otto R, Buehler H, Freiburghaus AU, Siegenthaler W. Evolution and regression of pancreatic calcification in chronic pancreatitis. A prospective long-term study of 107 patients. *Gastroenterology* 1988; **95**: 1018-1028 [PMID: 3410215]

56 **Lankisch PG**, Otto J, Erkelenz I, Lembcke B. Pancreatic calcifications: no indicator of severe exocrine pancreatic insufficiency. *Gastroenterology* 1986; **90**: 617-621 [PMID: 3943692]

57 **Sahai AV**. EUS and chronic pancreatitis. *Gastrointest Endosc* 2002; **56**: S76-S81 [PMID: 12297754 DOI: 10.1016/S0016-5107(02)70091-6]

58 **Seicean A**. Endoscopic ultrasound in chronic pancreatitis: where are we now? *World J Gastroenterol* 2010; **16**: 4253-4263 [PMID: 20818808 DOI: 10.3748/wjg.v16.i34.4253]

59 **Stevens T**, Dumot JA, Zuccaro G, Vargo JJ, Parsi MA, Lopez R, Kirchner HL, Purich E, Conwell DL. Evaluation of duct-cell and acinar-cell function and endosonographic abnormalities in patients with suspected chronic pancreatitis. *Clin Gastroenterol Hepatol* 2009; **7**: 114-119 [PMID: 18955165 DOI: 10.1016/j.cgh.2008.09.002]

60 Quantification of Pancreatic Function Using a Clinically Feasible Short Endoscopic Secretin Test. *Pancreas* 2013; [PMID: 23921960 DOI: 10.1097/MPA.0b013e3182847a86]

61 **Rehnitz C**, Klauss M, Singer R, Ehehalt R, Werner J, Büchler MW, Kauczor HU, Grenacher L. Morphologic patterns of autoimmune pancreatitis in CT and MRI. *Pancreatology* 2011; **11**: 240-251 [PMID: 21625195 DOI: 10.1159/000327708]

62 **Law R**, Bronner M, Vogt D, Stevens T. Autoimmune pancreatitis: a mimic of pancreatic cancer. *Cleve Clin J Med* 2009; **76**: 607-615 [PMID: 19797461 DOI: 10.3949/ccjm.76a.09039]

63 **Hocke M**, Ignee A, Dietrich CF. Contrast-enhanced endoscopic ultrasound in the diagnosis of autoimmune pancreatitis. *Endoscopy* 2011; **43**: 163-165 [PMID: 21165827]

64 **Yassa NA**, Yang J, Stein S, Johnson M, Ralls P. Gray-scale and color flow sonography of pancreatic ductal adenocarcinoma. *J Clin Ultrasound* 1997; **25**: 473-480 [PMID: 9350565]

65 **Dietrich CF**, Braden B, Hocke M, Ott M, Ignee A. Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound. *J Cancer Res Clin Oncol* 2008; **134**: 635-643 [PMID: 17952469 DOI: 10.1007/s00432-007-0326-6]

66 **Faccioli N**, Crippa S, Bassi C, D'Onofrio M. Contrast-enhanced ultrasonography of the pancreas. *Pancreatology* 2009; **9**: 560-566 [PMID: 19657211 DOI: 10.1159/000225960]

67 **Takeda K**, Goto H, Hirooka Y, Itoh A, Hashimoto S, Niwa K, Hayakawa T. Contrast-enhanced transabdominal ultrasonography in the diagnosis of pancreatic mass lesions. *Acta Radiol* 2003; **44**: 103-106 [PMID: 12631008]

**P-Reviewers** Lee SW, Neri V  **S-Editor** Wen LL  **L-Editor**  **E-Editor**

**Figure 1 Pancreas and the surrounding anatomical landmarks.** Left: B-mode image (1-5 MHz); Right: B-mode image with a 12-15 MHz transducer. Details shown with high resolution. MR: Musculus rectus abdominis; RLL: Right liver lobe; Cap: Caput pancreatis; Cor: Corpus pancreatis; cau: Cauda pancreatis; msa: Superior mesenteric artery; duo: Duodenum; Ao: Aorta.

**Figure 2 Left lateral side scan shows the pancreatic tail (Cauda) using the spleen as acoustic window.**

**Figure 3 Perfusion analysis of the pancreas.** Dual view of contrast-enhanced ultrasonography examination of the pancreas in a healthy volunteer. 1.5 mL bolus of Sonovue was given as a bolus and after approximately 45 s the area of interest was exposed to high MI ultrasound bursting the bubbles in the imaging plane. A motion correcting analyzing software was used (DCE-US, <http://www.isibrno.cz/perfusion/>). A region of interest have been drawn including the head and body of the pancreas. (Unpublished data).

**Figure 4 Ultrasound targeted treatment of pancreatic cancer using combined microbbubbles and a chemotherapeutic.** Left: B-mode frame. Right: The main tumor with spiculas, clearly demarked, using the sonoporation settings. Tu: Tumor; Ao: Aorta.

**Figure 5 Endoscopic ultrasound with elastography of chronic pancreatitis.** Endoscopic ultrasonography B-mode sonogram (right) and an elastogram superimposed a sonogram (left). In this image of the pancreatic head, hyperechoic foci and strands are seen in the parenchyma, as well as inhomogeneous echogenecity, which are signs of chronic pancreatitis. The elastogram shows predominantly a blue, indicating harder tissue, and green representing intermediate hardness in a honeycomb pattern over the pancreatic tissue.

**Figure 6 Endoscopic ultrasonography B-mode sonogram and elastogram of lymph node in chronic pancreatitis.** The sonogram (right) shows a lymph node as a hypoechoic oval shape surrounded by more echogenic tissue in the liver hilum. This lymp node approx. 18 mm × 10 mm, appeared in the liver hilum of a patient with chronic pancreatitis. On the left, the lymph node is not harder than the surrounding tissue as the predominant color hue is green. This finding is frequent in reactive lymph nodes, and may be a sign of benign etiology.

**Figure 7 Advanced chronic pancreatitis.** Classical signs in advanced chronic pancreatitis: main pancreatic duct dilatation in an atrophic organ with sharp, irregular contours, calcifications and small cysts. The pancreatic head is outlined.

**Figure 8 An example of contrast enhanced ultrasound in advanced chronic pancreatitis.** The parenchymal enhancement is clearly irregular reflecting the parenchymal heterogenicity, calcifications and focal inflammation.

**Figure 9 Elastography of the pancreas in moderate chronic pancreatitis.** The colors show tissue hardness; The scale on the left defines the color code: Blue is hard, red is soft, yellow and green are intermediate. The elastogram shows predominantly soft (red) tissue with parts of green and yellow, indicating harder pancreatic tissue.

**Figure 10 Early chronic pancreatitis.** Typical signs in early chronic pancreatitis: lobularity (L), stranding (S), hyperechoic foci (H) and honeycombing (Ho). Pancreatic body (Corpus). This subtle changes are usually only seen in endoscopic ultrasonography.

**Figure 11 Autoimmune pancreatitis.** Enlarged pancreas with a tumorous formation in the head. The inflammatory lesion is isoechoic to the rest of the pancreas but still clearly visible.

**Figure 12 Malignant tumor of the pancreatic body: Ductal adenocarcinoma.** The tumor is clearly visible on B-mode, left upper image. Contrast enhanced ultrasonography: The characteristics are hypochogenicity and diffuse contours. The plastic biliary stents are clearly noticeable on B-mode, right upper image. Cho: Biliary duct (ductus choledochus); Cap: Caput pancreatis; Tu: Tumor.